Golding Amit, Haque Uzma J, Giles Jon T
Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA.
Rheum Dis Clin North Am. 2007 May;33(2):319-43, vi-vii. doi: 10.1016/j.rdc.2007.01.001.
Additional research is needed to establish the safety of biologic agents in pregnancy and lactation. The practitioner should convey information regarding the natural history of rheumatoid arthritis during pregnancy and safety issues related to pharmacotherapies to every woman of childbearing age with RA, well before conception and pregnancy, to ensure optimal outcomes.
需要进行更多研究以确定生物制剂在妊娠和哺乳期的安全性。从业者应在受孕和怀孕前，尽早向每位患有类风湿性关节炎的育龄妇女传达有关妊娠期间类风湿性关节炎的自然病程以及与药物治疗相关的安全问题的信息，以确保获得最佳结果。
